Check for updates

OPINION ARTICLE

siRNA knockdown validation 101: Incorporating negative controls in antibody research [version 1; peer review: 3 approved]

Will Olds, Jason Li

Proteintech Group, Rosemont, IL, USA

v1 First published: 09 Mar 2016, 5:308
<https://doi.org/10.12688/f1000research.8159.1>
 Latest published: 09 Mar 2016, 5:308
<https://doi.org/10.12688/f1000research.8159.1>

Abstract

More antibody validation protocols would identify non-specific reagents – a major source of irreproducible research – with the inclusion of negative controls. This article presents an overview of one such method: siRNA knockdown. The authors outline a general protocol, the knockdown mechanism, and tips for evaluating knockdown experiments.

Keywords

knockdown , siRNA , negative control , specificity , Western Blot , shRNA , transfection , vector

This article is included in the **Antibody** Validations gateway.

Open Peer Review

Approval Status

	1	2	3
version 1			
09 Mar 2016	view	view	view

1. **Md. Golam Sharoar**, Cleveland Clinic, Cleveland, USA
2. **Angus C. Nairn**, Yale School of Medicine, New Haven, USA
3. **Shi-Jiang Lu**, Ocata Therapeutics Inc, Marlborough, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding authors: Will Olds (will@ptglab.com), Jason Li (jasonl@ptglab.com)

Competing interests: Will Olds is a scientific officer at Proteintech Group. Jason Li is CEO of Proteintech Group.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2016 Olds W and Li J. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Olds W and Li J. **siRNA knockdown validation 101: Incorporating negative controls in antibody research [version 1; peer review: 3 approved]** F1000Research 2016, 5:308 <https://doi.org/10.12688/f1000research.8159.1>

First published: 09 Mar 2016, 5:308 <https://doi.org/10.12688/f1000research.8159.1>

Introduction

Poor quality, unverified antibodies are a major factor underlying the crisis of reproducibility in research¹, resulting in an estimated \$800 million of waste each year² and a ten-fold spike in retractions over the past decade³. Behind those numbers are researchers with mounting frustration each time a new batch of reagents fails to reproduce their previous work. If we as a scientific community are to eliminate this problem plaguing our research, we must develop new and more thorough validation methods to fortify and standardize routine studies.

We invite industry to respond to the need for more rigorous validation by incorporating negative controls, an essential part of experimental design that has nonetheless been overlooked historically by antibody manufacturers and distributors. Companies typically validate with Western blots but seldom test routinely whether antibodies still produce a signal when the target protein is suppressed or removed.

Short interfering RNA (siRNA) knockdown is a technology that makes routine use of this strategy more feasible. This technology degrades target messenger RNA to 'knock down' the production of a protein in the cell. The combination of siRNA-treated cells and a specific antibody will result in a significant drop in signal compared to an untreated sample by Western blot (Figure 1).

siRNA knockdown has not been the only validation initiative put forward to identify non-specific antibodies⁴. CRISPR and other gene editing methods knock out a gene from DNA, preventing the associated protein from ever being produced. By default, an antibody binding to any protein in this environment is binding to the wrong protein. Knock-out is a powerful negative control,

however one concern with this method is the risk of cell death when a target protein is vital to cell survival. Other initiatives dispense with negative controls and verify positive identification instead. Mass spectrometry, for example, yields unique spectra that differentiate an antibody-bound protein of interest from any other bound molecule but is limited only to those proteins that can be immunoprecipitated.

While all of these approaches sound simple, their methodologies can be complex. Anyone seeking a deeper understanding of siRNA knockdown validation studies, or considering their own validation protocol, may find the following overview useful. These steps are based on Proteintech methods, which have been tested and refined over years. However, they are by no means the only way to perform this validation.

Design and engineer a vector

Selecting a target and designing an appropriate vector to transfect into cells is a relatively straightforward process, with an abundance of literature and online resources available to guide the process (RNAi Consortium, Dharmacon, Ui-Tei, and Genelink). The actual engineering, of course, requires a bit more hands-on finesse to create the short hairpin RNA that is the precursor form of the siRNA. The ultimate aim is to design two single-stranded 19-22mer DNA oligonucleotides (one sense strand, one antisense strand) whose transcription products will eventually anneal together, linked at one end by a short loop sequence. Proteintech uses the loop sequence *TTCAAGACG*.

Transfect and culture

Once the vector has been generated and produced in sufficient quantity, scientists need to determine an appropriate transfection method for delivery into cells. Upon successful transfection, the cells transcribe the foreign DNA to generate the shRNA described above (Figure 2). Afterward, Dicer processes the shRNA into siRNA by removing the loop sequence. The resulting siRNA binds with RISC (RNA-induced silencing complex), which separates the two strands of the RNA and activates the complex. RISC remains bound to one strand, that complementarily binds to a target mRNA and cleaves it. This suppresses production of the associated protein. Scientists need to allow time for the biological processes to be carried out, while culturing the cells to produce enough sample for a Western blot.

Cell death can be a major source of frustration, particularly if the target protein is vital to cell survival. Fortunately, most cells can propagate normally if the protein is suppressed, but not completely eliminated. In such cases, knockdown methods can be fine tuned and are likely a preferred alternative to knock out validation, which prevents any transcription through gene editing.

Test and evaluate

A strong signal for the empty-vector cells next to a weak signal for the siRNA-transfected cells in a Western blot means that the antibody is specific and that the knockdown experiment was successful. Any nonspecific bands should raise questions, as these

Figure 1. siRNA result of AKT1 antibody (10176-2-AP) with siRNA control, HEK293 control and siRNA AKT1.

Figure 2. An overview of the biological pathway of siRNA knockdown.

could indicate that the antibodies themselves are nonspecific. Bands should also be consistent across all lanes of the Western blot membrane. If not, something may have gone wrong in the experiment, and protocol and experimental design should be reviewed.

While the value of negative controls to antibody validation protocols should not be understated, it is also understood that such validation is not widely available and that it consumes time and resources to perform in individual labs. Thorough Western blot validation with only positive controls can be a second-best alternative, provided that there is a sufficient quantity of data, and corroborated by published studies that reference the reagent catalog number and manufacturer. We encourage the development and use of negative controls such as siRNA knockdown as the new standard in antibody

validation. Doing so will elevate reproducible research and accelerate scientific progress.

Author contributions

WO wrote and JL critically reviewed and edited the article. All authors have agreed to the final content of the manuscript.

Competing interests

Will Olds is a scientific officer at Proteintech Group. Jason Li is CEO of Proteintech Group.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. Baker M: **Reproducibility crisis: Blame it on the antibodies.** *Nature*. 2015; **521**(7552): 274–276. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Baker M: **Antibody anarchy: A call to order.** *Nature*. 2015; **527**(7579): 545–551. [PubMed Abstract](#) | [Publisher Full Text](#)
3. McLeod J, Ferrigno PK: **Antibody Alternatives.** *The Scientist*. 2016. [Reference Source](#)
4. Dance A: **Exercises for Your Abs.** *The Scientist*. 2016. [Reference Source](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 23 March 2016

<https://doi.org/10.5256/f1000research.8776.r12834>

© 2016 Lu S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Shi-Jiang Lu

Ocata Therapeutics Inc, Marlborough, MA, USA

Antibody has been widely used in bio-research fields, and discrepancies among publications using antibodies from different vendors are frequently observed. The main reason is the specificity of antibodies used by different researchers. This article described a siRNA knockdown strategy to validate the specificity of antibodies, which provides a negative control that may serve as an alternative way to exclude non-specific antibodies. This strategy may, at least partially, solve the irreproducible results among researches using antibodies as detecting reagents.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 14 March 2016

<https://doi.org/10.5256/f1000research.8776.r12835>

© 2016 Nairn A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Angus C. Nairn

Department of Psychiatry, Yale School of Medicine, New Haven, USA

The suggestion to routinely incorporate negative controls such as siRNA knockdown for the validation of antibodies is a good one. The article is clearly written and timely. The authors might have included an appropriate reference to the discovery of the siRNA knockdown mechanism. Further, the authors might have discussed the basis for choice of cell line used as the positive control.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 11 March 2016

<https://doi.org/10.5256/f1000research.8776.r12832>

© 2016 Sharoar M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Md. Golam Sharoar

Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

The article describes an excellent method of antibody specificity validation before commercial release. Non-specific binding of antibody is a major constrain for reproducibility and for acceptable quality of data. Thus, knocking down the target gene utilizing siRNA is a suitable method to determine the specificity of the antibody. The author explained a suitable method to develop high quality antibody commercialization. I believe that the article is appropriate as published in F1000Research.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Comments on this article

Version 1

Reader Comment 14 Apr 2016

Anita Bandrowski, University of California, San Diego, USA

This is a well written piece, but you have forgotten one important part. The method of publishing information about an antibody. It does not matter how much you validate if the antibody you are validating is not identified sufficiently to actually determine which antibody is being used!

For your 10176-2-AP antibody, that you use as an example. Please add the RRID to it so that the data is kept "safe" and uses of this reagent are tracked through the literature.

Please see the recommendations from F1000 instructions to authors:

<http://f1000.com/resources/F1000Research-Antibody-Validation-Article-Template.docx>

- which states "Research Resource identifier (**RRID**) for each antibody, model organism, or software tool used, as can be found on <http://scicrunch.com/resources>"

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research